New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine ...Middle East

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1 Patients receiving...

Read More Details
Finally We wish PressBee provided you with enough information of ( New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine )

Also on site :

• 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
• Prabowo hails BRICS entry, reaffirms Indonesia’s non-aligned stance
• Israel-Iran war stretches into a second week without diplomatic breakthrough